FDA Requires Warning for Guillain-Barré Syndrome in Prescribing ...
Jan 7, 2025 · The FDA requires a GBS warning for RSV vaccines Abrysvo and Arexvy due to increased risk within 42 days post-vaccination. Clinical trials and postmarketing data show rare …
Arexvy (RSV Vaccine): Usage, Side Effects, Warnings - Drugs.com
Jun 17, 2024 · Arexvy vaccine works by inducing an immune response against the RSVpreF3 antigen, the main protein found on the surface of RSV. Arexvy is the RSV vaccine from GSK. …
New data for Arexvy, GSK’s respiratory syncytial virus vaccine, …
Oct 24, 2024 · GSK plc (LSE/NYSE: GSK) today announced new preliminary data for Arexvy (respiratory syncytial virus vaccine, recombinant adjuvanted) in adults aged 18-49 at increased …
FDA Approves First Respiratory Syncytial Virus (RSV) Vaccine
Today, the U.S. Food and Drug Administration approved Arexvy, the first respiratory syncytial virus (RSV) vaccine approved for use in the United States. Arexvy is approved for the...
RSV Vaccine Labeling Updated With Guillain-Barré Syndrome …
5 days ago · The prescribing information for Abrysvo ® (respiratory syncytial virus [RSV] vaccine) and Arexvy ® (RSV vaccine, adjuvanted) has been updated to include a new warning …
FDA approves first vaccine for RSV, a moment six decades in the ... - CNN
May 3, 2023 · After a 60-year scientific quest, the world has its first vaccine to protect against respiratory syncytial virus, or RSV – and more are on the way. On Wednesday, the US Food …
GSK Presents Positive Data for AREXVY, Its Respiratory Syncytial …
Oct 8, 2024 · AREXVY is the world’s first RSV vaccine and was approved based on exceptional efficacy in adults aged 60 and older including those who are at increased risk due to certain …
New Data for AREXVY, GSK’s Respiratory Syncytial Virus Vaccine, …
Oct 24, 2024 · PHILADELPHIA-- (BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced new preliminary data for AREXVY (Respiratory Syncytial Virus Vaccine, …
GSK Posts New Data From Phase III Study on RSV Vaccine Arexvy
Oct 10, 2024 · New data from GSK's phase III study evaluating a single dose of RSV vaccine Arexvy indicates protection over three RSV seasons in adults aged 60 years and above.
GSK shares positive data for AREXVY, its respiratory syncytial virus ...
Jun 21, 2023 · PHILADELPHIA--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced new data from the AReSVi-006 (Adult Respiratory Syncytial Virus) phase III trial …